Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Shandong University Qilu Hospital, Jinan, Shandong, and Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong, China.
Department of Endocrinology, Peking University First Hospital, Beijing, China.
Biosci Rep. 2019 Apr 30;39(4). doi: 10.1042/BSR20181729.
The morbidity of type 2 diabetes mellitus (T2DM) has been increasing rapidly worldwide. Tangminling pill, consisting of ten Chinese herbal medications, is usually prescribed for T2DM in mainland China. Whether treatment with Tangminling can improve clinical outcomes of T2DM patients was still debated. Four studies comparing Tangminling vs. placebo treatment in T2DM patients were included and 767 T2DM patients were enrolled in our analyses. Tangminling treatment exhibited better efficacy than placebo in reducing hemoglobin A1c (HbA1c) (1.11 vs. 0.32%; pooled weighted mean difference [WMD]: 0.80; 95% confidence interval [CI]: 0.65-0.96; <0.001), fasting plasma glucose (0.82 vs. -0.40 mM; WMD: 1.10; 95% CI: 0.56-1.64; <0.001), 2-h postprandial glucose (2-hr PG) (2.81 vs. 1.11 mM; WMD: 1.80; 95% CI: 1.72-1.88; <0.001), homeostatic model assessment-β level (4.28 vs. 0.41; WMD: 0.44; 95% CI: 0.27-0.61; <0.001), waist circumference (WC) (1.04 vs. 0.36 cm; WMD: 0.78; 95% CI: 0.37-1.19; <0.001) and body weight index (0.37 vs. 0.11 kg/m; WMD: 0.30; 95% CI: -0.00 to 0.61; =0.05). Tangminling pill might reduce glucose level and body weight and improve β-cell function in T2DM patients. Our study highlights the important role of Tangminling pill in the management of T2DM.
2 型糖尿病（T2DM）的发病率在全球范围内迅速上升。糖敏灵胶囊由十种中药组成，在中国内地常用于治疗 T2DM。然而，糖敏灵治疗是否能改善 T2DM 患者的临床结局仍存在争议。我们纳入了四项比较糖敏灵与安慰剂治疗 T2DM 患者的研究，共有 767 例 T2DM 患者纳入分析。与安慰剂相比，糖敏灵治疗可更显著降低糖化血红蛋白（HbA1c）（1.11 对 0.32%；加权均数差值 [WMD]：0.80；95%置信区间 [CI]：0.65-0.96；<0.001）、空腹血糖（0.82 对 -0.40 mM；WMD：1.10；95% CI：0.56-1.64；<0.001）、餐后 2 小时血糖（2-hr PG）（2.81 对 1.11 mM；WMD：1.80；95% CI：1.72-1.88；<0.001）、稳态模型评估-β 水平（4.28 对 0.41；WMD：0.44；95% CI：0.27-0.61；<0.001）、腰围（WC）（1.04 对 0.36 cm；WMD：0.78；95% CI：0.37-1.19；<0.001）和体重指数（0.37 对 0.11 kg/m；WMD：0.30；95% CI：-0.00 至 0.61；=0.05）。糖敏灵胶囊可能通过降低血糖水平和体重，改善 T2DM 患者的 β 细胞功能。本研究强调了糖敏灵胶囊在 T2DM 管理中的重要作用。
